ArticleFrontiers in oncology2026

Inhibitory effect of the multi-target TKI, anlotinib, in 5-FU resistant colorectal cancer HCT-8/15 cells: down regulation of drug resistance-associated protein expression.

Juan Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.